INT344060

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.06
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 6
Disease Relevance 3.65
Pain Relevance 1.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
liver 1
Esl1 (Mus musculus)
Pain Link Frequency Relevance Heat
sodium channel 66 100.00 Very High Very High Very High
Neuropathic pain 6 92.20 High High
Pain 6 91.16 High High
carbamazepine 72 90.88 High High
Analgesic 6 87.80 High High
antiepileptic Drug 114 87.28 High High
amygdala 6 85.40 High High
headache 30 78.32 Quite High
Dopamine 6 68.64 Quite High
gABA 6 67.60 Quite High
Disease Link Frequency Relevance Heat
Partial Seizures 84 99.92 Very High Very High Very High
Convulsion 210 96.80 Very High Very High Very High
Epilepsy 144 96.56 Very High Very High Very High
Exanthema 12 96.40 Very High Very High Very High
Neuropathic Pain 6 92.20 High High
Pain 6 91.16 High High
Nervous System Injury 6 90.96 High High
Hyponatremia 12 83.84 Quite High
Dizziness 30 80.16 Quite High
Headache 30 78.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
With regard to the safety and tolerability of ESL in patients with epilepsy, adverse effects occurred mainly during the early treatment phase; intensity was mild to moderate, and no significant differences in the incidence of adverse effects were apparent between ESL and placebo after six weeks of treatment (Table 2).16,24,29,30 Of note, the incidence of rash was 0.3% with placebo, 0.5% with ESL 400 mg, 1.1% with ESL 800 mg, and 3.2% with ESL 1200 mg.
Gene_expression (apparent) of ESL associated with exanthema and epilepsy
1) Confidence 0.06 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.39 Pain Relevance 0
0.001 versus ESL 400 mg and placebo), and 32.8% (ESL 1200 mg, P ?
Gene_expression (versus) of ESL
2) Confidence 0.06 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.76 Pain Relevance 0.11
ESL is a prodrug of eslicarbazepine (the active entity responsible for pharmacologic effects), and is rapidly and extensively hydrolyzed during first pass by liver esterases after oral administration.
Gene_expression (prodrug) of ESL in liver
3) Confidence 0.06 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Abstract Doc Link PMC2987506 Disease Relevance 1.02 Pain Relevance 0.13
The pharmacokinetic and pharmacodynamic profile of eslicarbazepine, as well as the mechanisms of action, differ from those of the well known and frequently used VGSC blockers.16,27 ESL (BIA 2-093, S-(?)
Gene_expression (those) of ESL associated with sodium channel
4) Confidence 0.06 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.49 Pain Relevance 0.61
0.001 versus ESL 400 mg and placebo), and 32.8% (ESL 1200 mg, P ?
Gene_expression (versus) of ESL
5) Confidence 0.06 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.78 Pain Relevance 0.11
Because eslicarbazepine is chemically related to carbamazepine and oxcarbazepine, with differences at the 10,11 position, eslicarbazepine is not susceptible to metabolic autoinduction, and might have a favorable safety profile and a low drug interaction potential.12–21 Unlike oxcarbazepine, which is metabolized to both (S)-licarbazepine (80%) and (R)-licarbazepine (20%), eslicarbazepine is metabolized solely to (S)-licarbazepine, although it subsequently undergoes a minor chiral inversion (through oxidation to oxcarbazepine) to (R)-licarbazepine.22 Other than oxcarbazepine, ESL avoids unnecessary production of enantiomers or diastereoisomers of metabolites and their conjugates.23 After Phase III trials were completed (mainly in Europe and South America), ESL was approved by the European Medicines Agency and is now available in most European countries as adjunct therapy for adult patients with refractory partial seizures.24 Of note, no study has been conducted in the US so far.
Gene_expression (production) of ESL associated with partial seizures and carbamazepine
6) Confidence 0.05 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.21 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox